By Alistair Smout
LONDON (Reuters) – Pfizer’s COVID-19 vaccine produced three and a half times larger antibody responses in older adults when the second dosing was delayed to 12 weeks after the first, the British study said.
The study published Friday was the first to directly compare Pfizer’s immune response from the three-week dosing period tested in a clinical trial and an extended 12-week interval recommended by British officials to. To those who are at least partially more at risk Protect quickly
After the UK moved to extend the time between dosing, Pfizer’s BioNTech and vaccine company said there was no data to back up the move. However, Pfizer said public health considerations in addition to clinical trials could be taken into account.
“Our studies show that the maximum antibody response after a second Pfizer vaccination was significantly improved in older adults when this was delayed by 12 weeks,” said study author Helen Parry at the university. Birmingham said.
Video: Dr. Fasi: Make sure you get the second shot.
The UK began rolling out Pfizer’s vaccine before it changed its drug policy, meaning quite a few people getting their vaccine early will get a second vaccination in three weeks. Later
The study, which has not been peer reviewed, looked at 175 people between the ages of 80 and 99 and found that expanding the second period to 12 weeks increased the antibody response up to 3.5 times compared with the Those who have been in the last three weeks.
Antibodies are part of the immune system and the vaccine also produces T cells.The maximum T cell response was higher in the group, with a 3-week interval between doses, and the authors caution not to conclude that the protected individuals were up. How to stay with the dosing schedule they have been given?
However, based on data showing good protection against single Pfizer hospitalization and deaths, Public Health England said the study provides further evidence to support UK guidelines.
“The UK’s approach to delaying a second dose has really worked,” said Gayatri Amirthalingam. Epidemiology adviser to Public Health England told reporters.
(Reporting by Alistair Smout; (Edited by Alexander Smith)